Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for...

Dr Ian Chau - The Royal Marsden, London, UK

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau - The Royal Marsden, London, UK )

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

European Cancer Organisation - Time to Act

Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands

European Cancer Organisation - Time to Act ( Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands )

European Cancer Organisation: Time To Act

Professor Mark Lawler - Queens University Belfast, Belfast, UK

European Cancer Organisation: Time To Act ( Professor Mark Lawler - Queens University Belfast, Belfast, UK )

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems

Special issue authors and funders

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems ( Special issue authors and funders )

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small...

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer